Buy Andexxa Online (coagulation factor Xa (recombinant), inactivated-zhzo)

Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a medication used for the treatment of patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

This is the first approved antidote for apixaban- or rivaroxaban-treated patients with uncontrolled bleeds.

Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) was approved by the EMA in April 2019 under the trade name Ondexxya (andexanet alfa). It is available to order as well. See Ondexxya (andexanet alfa).

Package

4 single-use vials

Categories: All Medications, Haematology

Description
Reviews (0)

Description

Buy Andexxa Online (coagulation factor Xa (recombinant), inactivated-zhzo)

Introduction to Andexxa

Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) represents a pivotal advancement in the field of coagulation management. This product is specifically designed to address the needs of patients experiencing life-threatening or uncontrolled bleeding due to the use of factor Xa inhibitors. As a recombinant form of coagulation factor Xa, Andexxa functions as a groundbreaking antidote, providing healthcare professionals with a reliable solution for managing severe bleeding episodes.

Mechanism of Action

Andexxa works by binding to factor Xa inhibitors, thereby neutralizing their anticoagulant effects. This action helps to restore normal hemostasis in patients who require urgent reversal of anticoagulation. The administration of Andexxa is a critical intervention in emergency settings, where timely and effective treatment is essential. By counteracting the effects of factor Xa inhibitors, Andexxa enables the rapid stabilization of patients’ conditions, potentially saving lives.

Clinical Efficacy and Safety

Clinical trials have demonstrated the efficacy and safety of Andexxa in reversing the anticoagulant effects of factor Xa inhibitors. The product has been rigorously tested and received approval from regulatory authorities, ensuring its reliability in clinical practice. Healthcare providers can be confident in the ability of Andexxa to deliver consistent and predictable outcomes, making it an invaluable tool in the management of anticoagulation-related bleeding emergencies.

Conclusion

For healthcare professionals tasked with managing the complexities of anticoagulation therapy, the availability of Andexxa is a significant advancement. By offering a targeted and effective solution for the reversal of factor Xa inhibitors, Andexxa enhances the ability to provide prompt and effective care to patients in critical situations. Consider incorporating Andexxa into your therapeutic arsenal to improve patient outcomes in cases of severe bleeding.